Ilex/Millenium Campath
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alemtuzumab receives accelerated approval May 7 for treatment of B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and who have failed fludarabine (Berlex's Fludara) therapy. The company is considering whether to study Campath in combination with Fludara, and in sequential use following Fludara, for first-line treatment of patients with B-cell CLL. Studies of the agent are planned in prolymphocytic leukemia, multiple sclerosis and organ transplantation
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.